Company
LON:NSCI
EMV Capital plc is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies. With a strategic focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future, the group invests in, manages, and strengthens early stage IP-rich companies.
424 stories · page 7 of 22
"The K-POSTN assay has the potential to help healthcare professionals screen, identify and/or monitor people most at risk of osteoporotic fractures and other bone diseases, thus enabling early therapeutic intervention," said ProAxis CEO Dr
The issue is said to be unrelated to any safety or efficacy concerns with the drug combination
The initial arm of this phase II trial will assess people who have not yet been treated with checkpoint inhibitor drugs
The company invests in emerging life sciences and tech companies - and has uncovered a handful of hidden gems, say WHI Ireland
“We are seeking to address the continued disconnect between the fair value and growth opportunities of the group, and the current market cap," said Ilian Iliev
It is investing an initial £1mln in Martlet Capital, which has been set up to up to acquire minority interests in businesses in this hotbed of innovation
"The company is now well-positioned for future success"
The funding from this offering will support the continued development of PDS's lead HPV oncology candidate (PDS0101) in the three Phase II trials currently underway.
WHI Ireland has a sum-of-the-parts valuation for the shares of 162p - a 40% premium to the current price
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
NetScientific currently has a 5.7% stake in PDS Biotechnology, which is at the cutting edge of immuno-oncology
Archive
A look at some of the big movers in the small-cap world this week
"This placement provides further impetus behind our model of 'capital-light' investment combined with pro-active management and value-added support to our portfolio," said Ilian Ilev, NetScientific's CEO
“The data provide early evidence of notable clinical activity, and we saw effective tumour regression in these patients"
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
A look at some of the major movers in London on Monday
It is envisaged that the validation and initial commercialisation can be achieved largely from ProAxsis' existing resources
Investments and investor services
The easiest way to describe NetScientific is a ‘reset story’. By this I mean new management has come in, cut costs, refinanced, refocused, and, hopefully, put the business back on the guide rails to success.
The City broker pointed to the last fair value calculation for the assets held by the investment company, which specialises in life sciences and technology
Archive
A glance at some of the day's highlights from the Proactive Investors' newswire
